{
    "clinical_study": {
        "@rank": "146147", 
        "arm_group": [
            {
                "arm_group_label": "Inspiromatic followed by Aerolizer", 
                "arm_group_type": "Active Comparator", 
                "description": "volunteers will perform lung function pre and post Formoterol (a bronchodilator) inhalation. They will use either the Inspiromatic dry powder inhalers the delivery device. 3-60 days later participants will receive the same drug through the Aerolizer dry powder inhaler."
            }, 
            {
                "arm_group_label": "Aerolizer followed by Inspiromatic", 
                "arm_group_type": "Active Comparator", 
                "description": "volunteers will perform lung function pre and post Formoterol (a bronchodilator) inhalation. They will use either the Aerolizer dry powder inhalers the delivery device. 3-60 days later participants will receive the same drug through the Inspiromatic dry powder inhaler."
            }
        ], 
        "brief_summary": {
            "textblock": "Double-blind study, randomized, controlled, and crossover. Study recruited 30 volunteers\n      with stable asthma aged 8-18 years. Participants will perform lung function as part of the\n      routine follow-up then will receive a Foradil 12mcg either with an Aerolizer (a standard dry\n      powder inhaler)  or with the Inspiromatic (an active, breath synchronized innovative\n      inhaler). 3-60 days later participants will receive the same drug through the other inhaler.\n\n      Pre and post treatment (15 min, 30 min, 60 min) Lung function results, drug levels in the\n      blood, vital signs and side effects will be recorded."
        }, 
        "brief_title": "Safety and Efficacy of the Inspiromatic Inhaler in Comparison to the Aerolizer Inhaler When Delivering Formoterol", 
        "completion_date": {
            "#text": "December 2012", 
            "@type": "Anticipated"
        }, 
        "condition": "Asthma", 
        "condition_browse": {
            "mesh_term": "Asthma"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Children 8-18 years with Asthma\n\n          -  50<FEV1<80\n\n          -  Can perform Spirometry\n\n        Exclusion Criteria:\n\n          -  Poor cooperation\n\n          -  Pregnancy\n\n          -  Milk Allergy\n\n          -  Other lung disease\n\n          -  Prior familiarity with Aerolizer"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "18 Years", 
            "minimum_age": "8 Years"
        }, 
        "enrollment": {
            "#text": "30", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "September 22, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01711086", 
            "org_study_id": "0401-11-RMC"
        }, 
        "intervention": [
            {
                "arm_group_label": "Aerolizer followed by Inspiromatic", 
                "description": "Participants will receive Formoterol (Foradil) 12mcg via the Foradil Aerolizer inhaler while performing lung function as part of the and not differ from other routine follow-up", 
                "intervention_name": "Aerolizer Followed by Inspiromatic", 
                "intervention_type": "Device", 
                "other_name": "Foradil Inhaler"
            }, 
            {
                "arm_group_label": "Inspiromatic followed by Aerolizer", 
                "description": "Participants will receive Formoterol (Foradil) 12mcg via the Inspiromatic dry powder inhaler while performing lung function instead of getting it via the Foradil Aerolizer", 
                "intervention_name": "Inspiromatic followed by Aerolizer", 
                "intervention_type": "Device", 
                "other_name": "Inspiromatic dry powder experimental inhaler"
            }
        ], 
        "intervention_browse": {
            "mesh_term": "Formoterol"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": [
            "asthma", 
            "dry powder inhaler"
        ], 
        "lastchanged_date": "October 17, 2012", 
        "location": {
            "contact": {
                "email": "kids.lung@gmail.com", 
                "last_name": "Guy Steuer, M.D.", 
                "phone": "+972524249925"
            }, 
            "facility": {
                "address": {
                    "city": "Petach - Tikva", 
                    "country": "Israel"
                }, 
                "name": "Schneider Children Hospital"
            }, 
            "investigator": {
                "last_name": "Guy Steuer, M.D.", 
                "role": "Principal Investigator"
            }, 
            "status": "Not yet recruiting"
        }, 
        "location_countries": {
            "country": "Israel"
        }, 
        "number_of_arms": "2", 
        "official_title": "Double Blind Placebo Controlled Trial Checking the Safety and Efficacy of the Inspiromatic Inhaler in Comparison to the Aerolizer Inhaler When Delivering Formoterol", 
        "other_outcome": {
            "description": "K concentration, Glucose levels and drug level", 
            "measure": "Systemic absorption", 
            "safety_issue": "Yes", 
            "time_frame": "0 and 15 minutes post inhaltion"
        }, 
        "overall_contact": {
            "email": "kids.lung@gmail.com", 
            "last_name": "Guy Steuer, M.D.", 
            "phone": "+972524249925"
        }, 
        "overall_contact_backup": {
            "email": "hanhblau@post.tau.ac.il", 
            "last_name": "Hanna Blau, M.D.", 
            "phone": "+97239253654"
        }, 
        "overall_official": {
            "affiliation": "Schneider Children Hospital", 
            "last_name": "Guy Steuer, M.D.", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Not yet recruiting", 
        "oversight_info": {
            "authority": "Israel: Ministry of Health", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 1/Phase 2", 
        "primary_completion_date": {
            "#text": "November 2012", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Change in FEV1 from base line", 
            "measure": "FEV1", 
            "safety_issue": "No", 
            "time_frame": "We will measure FEV1 post treatment (15 min, 30 min, 60 min)"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01711086"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Rabin Medical Center", 
            "investigator_full_name": "Guy Steuer", 
            "investigator_title": "Guy Steuer, M.D.", 
            "responsible_party_type": "Sponsor-Investigator"
        }, 
        "secondary_outcome": {
            "description": "Change in heart rate, blood pressure", 
            "measure": "Vital signs", 
            "safety_issue": "Yes", 
            "time_frame": "Pre treatment and than 15 minutes post treatment"
        }, 
        "source": "Rabin Medical Center", 
        "sponsors": {
            "collaborator": [
                {
                    "agency": "Schneider Children's Medical Center, Israel", 
                    "agency_class": "Other"
                }, 
                {
                    "agency": "Inspiromedical Inc", 
                    "agency_class": "Other"
                }
            ], 
            "lead_sponsor": {
                "agency": "Guy Steuer", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "October 2012", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "October 2012"
    }
}